Anixa Biosciences, Inc. · NASDAQ:ANIX
Anixa Biosciences — Investor Presentation (May 2019)
22 slides from Anixa Biosciences's investor presentation, May 23, 2019
Slide 1: Amit Kumar, Ph.D., Chairman and CEO
Amit Kumar, Ph. D.. } - SChairtaan and CEO Gl BET ER com —
Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa Biosciences’ current
Slide 3: Anixa Corporate Background
Anixa Corporate Background Strategy ¢ Invent/in-license technology platforms ¢ Develop technology with partners ¢ Leverage existing infrastructure of partner © Low cash burn ¢ Sell, license or commercialize products NEW JERSEY A Key Collaborators UROLOGY Wirtua WU Wistar MOFFITT Gy) SCO Simei INSTIT
Slide 4: Two High Value Programs
Two High Value Programs Dynamic Interaction Between Tumors and the Immune System CAR-T: Cancer Immunotherapy Program * Chimeric Endocrine Receptor T-Cell (CER-T) technology: A new type of CAR-T ° Worldwide license o First indication - ovarian cancer o Platform for multiple cancer indications o Moffi
Slide 5: Therapeutic Program
Therapeutic Program y ¢ CAR-T Technology o Ovarian cancer ¢ Platform for other tumor indications Aanixa
Slide 6: CAR-T Process
CAR-T Process
Slide 7: CAR-T Technology: Background & Opportunity
CAR-T Technology : Background & Opportunity CAR- Technology has made great inroads in B-Cell cancers * Durable responses (50-80% of patients) + Multibillion dollar valuations and big pharma deals o Novartis - First approved product by FDA o Kymriah for ALL- Acute Lymphoblastic Leukemia e Second appr
Slide 8: Anixa's Unique CER-T Approach for Solid Tumors
Anixa’s Unique CER-T :Approach for Solid Tumors Chimeric Endocrine Receptor T-Cell Cancerous : Ovarian FSHR protein ——— f B-cell ci Cell (“Antigen”) - found Se v-anubedy fragment antigen only on ovarian cells engineered into T-cell _—_ <—— y —— FSH Follicle ww T-Cell T-Cell Stimulating engineered en
Slide 9: FSHR ONLY Expressed in Ovaries and Testis
FSHR ONLY Expressed in Ovaries and Testis (in healthy humans) 0.0025 ¢ However, FSHR expressed on the blood vessels of many TUMORS. ion 0.002 - Qn an 2 2 Only in Fetal Thymus 2 0.0015 ¢ Therefore, this therapy willbe z anti-angiogenic for many types of 5 0.001 cancer, enabling a portfolio of = thera
Slide 10: Pre-Clinical Data
Pre-Clinical Data FSH-Targeted chimeric receptors re-direct primary human T cells against FSHR+ ovarian cancer cells 707 -=-FSHCER 60-4 -& Mock 4 50: 40 30. 20 10: () 41 1:5 1:10 Target:Effector ratio Ovarian Cancer —— Breast Cancer ‘Source: Perales-Puchalt et al. “Follicle-stimulating hormone recep
Slide 11: Summary of Data on Anixa's CAR-T
Summary of Data on Anixa’s CAR-T + Published: Clinical Cancer Research, 23(2)January 15, 2017, 441-453 Tested Human CAR-T in immunocompromised mice against human Ovarian Cancer Tested Murine CAR-T in immunocompetent mice with murine ovarian cancer Tested Human CAR-T in immunocompromised mice against
Slide 12: Our Magic Bullet
Our Magic Bullet + Many tumors have blood vessels where FSHRis expressed even though healthy tissue does not show such expression © Physiologically, FSHR must be helpful in enabling tumors to create vasculature © Outside of the tumor margin, FSHR on blood vessels disappears + Our FSHR targeted CAR-T
Slide 13: Our CAR-T Program
Our CAR-T Program Clinical Cancer Research, 23(2)January 15, 2017, 441-453 « Exclusive World Wide License from The Wistar Institute ¢ Pre-IND work at Moffitt Cancer Center lead by highly experienced team * Cost for Pre-IND work is about $1.1 MM * Cli nical Trial Single Site, Open Label, Dose-Escalat
Slide 14: Diagnostic Program
Diagnostic Program y ¢ Liquid Biopsy o Prostate and breast cancer ¢ Platform for other tumor indications = Aanixa
Slide 15: Early Cancer Detection — Liquid Biopsy
Early Cancer Detection — Liquid Biopsy Anixa is developing a blood test for early cancer detection called Cchek™ €chek’ Early Cancer Detection Goal: To determine a patient's cancer status from a simple blood draw without a biopsy Aanixa
Slide 16: Competing Liquid Biopsy Approaches
Competing Liquid Biopsy Approaches * Circulating tumor DNA (ctDNA) All these approaches require * Circulating tumor Cells (CTCs) the tumor to be large enough . . to shed these markers into * Circulating tumor Exosomes the blood stream ¢ Other biomarkers coming directly from tumor Anixa’s Orthogonal
Slide 17: Artificial Intelligence (AI) Analysis
Artificial Intelligence (Al) Analysis Training Calls Neural Network Patient . Sample Normal Patient Samples aw ee? Cancer Patient Samples Malignancy SS or Normal Manixa
Slide 18: Early Studies: Multiple Cancer Types
Early Studies: Multiple Cancer Types (Stages 1- 4) Samples amples used in training: 150 Breast Prostate | Lung Colon | Osteosarcoma (bone cancer) Tu or Types Pancreatic Wecnome | orca wen | Leiomyosarcoma (cancer of the soft tissue) Bladder Ronen | Endometrial | Thyroid | Liposarcoma (cancer of the
Slide 19: Breast Cancer Screening Study
Breast Cancer Screening Study (Stages 1 and 2) Samples used in ) training: 132 Aanixa
Slide 20: Prostate Cancer Screening Studies
Prostate Cancer Screening Studies (Stages 1 -4) Internal Study Samples Used in training: 100 Memorial Sloan Kettering Study Samples Used\ in training: \ 137 Aanixa
Slide 21: Anixa's Liquid Biopsy
Anixa’s Liquid Biopsy « We monitor the patient’s white blood cells to detect tumors + We let the the patients body tell tell us there is a tumor + We do NOT measure tumor DNA, Circulating Tumor Cells or Tumor Exosomes « We combine Flow Cytometry and Artificial intelligence to perform the analysis ¢
Slide 22: Anixa's Value-Creating, Near-Term Milestones
Anixa’s Value-Creating, Near-Term Milestones Therapeutic Program Additional FDA meetings Filing of IND for clinical trial Approval of IND by FDA Patient recruitment First patient dosed and initiation of clinical trial Initiate pre-clinical projects on other tumors- Magic Bullet Diagnostics Program S